Tibet Rhodiola Pharmaceutical Holding Co Capital Reinvestment Ratio
Tibet Rhodiola Pharmaceutical Holding Co capital reinvestment ratio. Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥297.86 Million) in capital expenditures (CN¥4.98 Million). Check Tibet Rhodiola Pharmaceutical Holding Co (600211) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Capital reinvestment ratio of Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. This chart tracks Tibet Rhodiola Pharmaceutical Holding Co's Capital Reinvestment Ratio across 25 annual periods. Also explore net asset momentum of Tibet Rhodiola Pharmaceutical Holding Co to track the company's year-over-year net asset growth rate.
Tibet Rhodiola Pharmaceutical Holding Co Capital Reinvestment Ratio by Year (1999–2025)
Tibet Rhodiola Pharmaceutical Holding Co capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see Tibet Rhodiola Pharmaceutical Holding Co (600211) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | CN¥1.03 Billion | CN¥15.96 Million | ▼ -58.9% |
| 2024 | 0.04x | CN¥994.79 Million | CN¥37.60 Million | ▲ +88.6% |
| 2023 | 0.02x | CN¥1.08 Billion | CN¥21.69 Million | ▼ -83.5% |
| 2022 | 0.12x | CN¥837.38 Million | CN¥101.96 Million | ▼ -89.5% |
| 2021 | 1.16x | CN¥366.53 Million | CN¥425.58 Million | ▲ +124.7% |
| 2020 | 0.52x | CN¥428.17 Million | CN¥221.29 Million | ▲ +416.4% |
| 2019 | 0.10x | CN¥489.59 Million | CN¥49.00 Million | ▲ +23.9% |
| 2018 | 0.08x | CN¥289.22 Million | CN¥23.37 Million | ▼ -98.8% |
| 2017 | 6.65x | CN¥91.46 Million | CN¥607.98 Million | ▲ +17152.2% |
| 2016 | 0.04x | CN¥250.21 Million | CN¥9.64 Million | ▼ -51.6% |
| 2015 | 0.08x | CN¥133.93 Million | CN¥10.66 Million | ▼ -34.8% |
| 2013 | 0.12x | CN¥279.22 Million | CN¥34.12 Million | ▲ +55.4% |
| 2012 | 0.08x | CN¥56.20 Million | CN¥4.42 Million | ▼ -58.9% |
| 2011 | 0.19x | CN¥12.09 Million | CN¥2.31 Million | ▼ -85.9% |
| 2010 | 1.36x | CN¥1.90 Million | CN¥2.58 Million | ▲ +555.4% |
| 2009 | 0.21x | CN¥17.88 Million | CN¥3.70 Million | ▼ -7.5% |
| 2008 | 0.22x | CN¥21.46 Million | CN¥4.80 Million | ▼ -52.7% |
| 2006 | 0.47x | CN¥33.63 Million | CN¥15.90 Million | ▲ +26.5% |
| 2005 | 0.37x | CN¥18.92 Million | CN¥7.07 Million | ▼ -42.4% |
| 2004 | 0.65x | CN¥26.90 Million | CN¥17.45 Million | ▲ +33.8% |
| 2003 | 0.48x | CN¥47.20 Million | CN¥22.88 Million | ▼ -84.4% |
| 2002 | 3.11x | CN¥32.85 Million | CN¥102.14 Million | ▼ -39.7% |
| 2001 | 5.15x | CN¥15.47 Million | CN¥79.72 Million | ▼ -10.6% |
| 2000 | 5.76x | CN¥20.55 Million | CN¥118.45 Million | ▼ -79.5% |
| 1999 | 28.15x | CN¥2.25 Million | CN¥63.25 Million | — |